

Cardiology - Heart Failure Market Snapshot

Event: ACC- American College of Cardiology, March 29-31



HF Market Leaders



2008 Market Size: USD 7.58 b

GSK (NYSE:GSK), Johnson & Johnson (NYSE:JNJ): Natrecor-recombinant B-type natriuretic peptide (acute decompensated heart failure)

[JNJ's Natrecor shows unfavorable risk-benefit ratio, physicians say \(Pharmawire\)](#)

Novartis (NYSE:NVS): Rasilez-direct renin inhibitor

[Novartis/Speedel's hypertension drug Tekturna will likely be used as add-on therapy, physicians say \(Pharmawire\)](#)

[Novartis says a third of 'cluster' of new Tekturna clinical trials is in response to demand for outcome data \(Pharmawire\)](#)

Amgen (NASDAQ:AMGN)/Cytokinetics (NASDAQ:CYTK): CK-1827452-direct activator of cardiac myosin (stable heart failure)

[Cytokinetics' CK-1827452 novel heart failure drug may fill unmet medical need, but larger studies are needed to rule out risk of ischemia - physicians \(Pharmawire\)](#)

[Cytokinetics' compound could be first oral therapy for chronic heart failure, physicians say, but remain cautious \(Pharmawire\)](#)

[Cytokinetics heart failure compound could be better tolerated than inotropes, company says; physicians say looks promising but still in early development \(Pharmawire\)](#)

Merck (NYSE:MRK): rolofylline-diruetic (acute heart failure)

[Merck's investigational rolofylline associated with improved dyspnea and preserved renal function in acute heart failure patients in a Phase III pilot study](#)

AstraZeneca (NYSE:AZN): Atacand-angiotensin receptor blocker (Chronic heart failure)

Biogen (NASDAQ:BIIB)/CV Therapeutics (NASDAQ:CVTX): Adentri-A1 adenosine receptor antagonist (acute decompensated HF)



Unpartnered Targets in Development

Neurocrine Biosciences (NASDAQ:NBIX): USD 70.5m in cash and cash equivalents, cash burn 13.4m

Urocortin 2-CRF₂ peptide agonist

[Neurocrine BioSciences will look to partner heart failure compound next year but regulatory pathway is uncertain, CEO says \(Pharmawire\)](#)

Program on hold until partnered.

Aastrom Biosciences (NASDAQ:ASTM): USD 16.3m in cash and cash equivalents, cash burn 13.8m

Cardiac Repair Cells (dilated cardiomyopathy)

[Aastrom Biosciences' Phase II IMPACT-DCM trial allowed to resume](#)

Phase II data expected June 2010

ARCA Biopharma (NASDAQ:ABIO): USD 59.1m in cash and cash equivalents and MS, cash burn 13.7m

Genaro-genetically-targeted beta-blocker

PDUFA May 31, 2009

Corthera: Raised USD 23m in Series C financing December 2007

Relaxin naturally occurring polypeptide hormone that increases global arterial compliance (acute heart failure, acute decompensated heart failure)

[Corthera prepared to commercialize relaxin on its own; could go public next year, CEO says \(Pharmawire\)](#)

Phase II data expected 1Q09.

Angioblast Systems

Revascor-Mesenchymal Precursor Cells (congestive heart failure)

[Angioblast Systems in talks for strategic alliance; could consider stake sale or IPO, VP says \(Pharmawire\)](#)

[Mesoblast is a takeover target and is open to bidder approaches; plans to increase stake in Angioblast, founder says \(Pharmawire\)](#)

Phase II data expected July 2011.

Angion Biomedica Corp

BB3-HGF mimetic (congestive heart failure)

Recently completed Phase II trial, December 2008.

Aldagen: Raised 18.4m in financing August 2008

ALD-201-ALDH^{br} stem cells (ischemic heart failure)

Phase II data expected December 2011

t2Cure: Financed by Entrepreneurs Fund BV

t2c001-AMI -progenitor cell based regenerative therapy (non-ischemic heart failure)